MAPT and tauopathy: Once clinically tested and approved, these second-generation radiopharmaceuticals could be used to select individuals based on their pathological status (strongly T+ individuals are generally A+), perform differential diagnoses with other tauopathies, and simultaneously stratify and classify diseases with 3R/4R or 4R tau deposition.